FindTrial
Sign In

MMR

BIOLOGICAL9 trials

Sponsors

Novartis Vaccines, McMaster University, Sanofi Pasteur, a Sanofi Company, NYU Langone Health, China National Biotec Group Company Limited

Conditions

HealthyHealthy VolunteersMeningitis, MeningococcalMeningococcal DiseaseMeningococcal MeningitisOpioid Use Disorder (OUD)PoliomyelitisVaccine

Phase 2

Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)
CompletedNCT00310856
Novartis VaccinesMeningococcal Meningitis
Start: 2005-06-30End: 2006-11-30Updated: 2018-10-09
Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
CompletedNCT00381615
Novartis VaccinesHealthy
Start: 2006-09-30End: 2008-08-31Updated: 2015-10-09
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
CompletedNCT00488683
Novartis VaccinesMeningococcal Disease
Start: 2007-07-31End: 2009-06-30Updated: 2014-10-01
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
Active, not recruitingNCT04464980
NYU Langone HealthOpioid Use Disorder (OUD)
Start: 2021-06-08End: 2027-01-31Updated: 2025-12-15

Phase 3

A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
CompletedNCT01000311
Novartis VaccinesMeningococcal Disease
Start: 2009-11-30End: 2011-11-30Updated: 2014-04-21
Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers
CompletedNCT03205371
Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal
Start: 2016-11-07End: 2018-07-19Updated: 2022-04-05

Phase 4

Homeopathic Vaccine Trial
NCT02825368
McMaster UniversityHealthy Volunteers
Start: 2016-09-30Updated: 2017-08-04
Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR
NCT04638985
China National Biotec Group Company LimitedVaccine
Start: 2020-11-13End: 2021-12-31Target: 600Updated: 2020-12-10
Booster Dose of sIPV Co-administered With MMR and HepA-I.
CompletedNCT06442449
Sinovac Biotech Co., LtdPoliomyelitis
Start: 2024-08-08End: 2025-10-10Updated: 2026-01-16

Related Papers

Immunogenicity and Safety of Sabin Strain Inactivated Poliovirus Vaccine Booster Dose Administered Separately or Concomitantly with Inactivated Hepatitis A Vaccine or Measles-Mumps-Rubella Combined Attenuated Live Vaccine: An Open-Labelled, Randomized, Controlled, Phase 4 Clinical Trial.
2025-10-23
Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD).
2025-01-201 citations
Randomised clinical trial of a 16 mg vs 24 mg maintenance daily dose of buprenorphine to increase retention in treatment among people with an opioid use disorder in Rhode Island: study protocol paper
BMJ Open2024-11-012 citations
Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial.
2024-04-231 citations
Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) Administered Concomitantly with Pneumococcal Conjugate Vaccine in Healthy Toddlers in the Russian Federation: a Phase III Randomized Study
Epidemiology and Vaccinal Prevention2023-01-092 citations
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study
Epidemiology and Infection2021-01-0114 citations